...
首页> 外文期刊>RSC Advances >An innovative strategy to obtain extraordinary specificity in immunofluorescent labeling and optical super resolution imaging of microtubules
【24h】

An innovative strategy to obtain extraordinary specificity in immunofluorescent labeling and optical super resolution imaging of microtubules

机译:一种创新的策略,以获得免疫荧光标记和光学超分辨率成像的显微特异性

获取原文
获取原文并翻译 | 示例
           

摘要

When performing immunofluorescent labeling of microtubules, Triton X-100 (TX100) is commonly used as the cell membrane permeabilization agent to improve the accessibility of antigens. Usually, before immunofluorescent labeling, cells are fixed first by aldehydes, followed by permeabilization with TX100. Here, we report an innovative immunofluorescent labeling strategy for microtubules with a meaningful alteration, that is, to treat cells with TX100 first and fix with aldehydes later. We proved that this subtle change can greatly improve the specificity of microtubular immunolabeling. However, treating cells first with TX100 can also severely disrupt the integrity of microtubules if an excessive amount of TX100 is used. Hence, TX100 is a "double-edged sword" in immunofluorescent labeling of microtubules and elaborative control of its dosage is required. In the experiment, we compared different immunofluorescent labeling protocols using various cell lines and found that treating cells with 0.02% TX100 before fixation is an optimal solution. Confocal laser scanning microscopy (CLSM), atomic force microscopy (AFM) and single molecule localization microscopy (SMLM) are utilized to verify the immunofluorescent labeling results performed via the presented unusual protocol. It is possible that such a modified immunofluorescent labeling protocol of microtubules can be generalized as a universal strategy.
机译:当进行微管的免疫荧光标记时,Triton X-100(TX100)通常用作细胞膜透化剂以改善抗原的可通过。通常,在免疫荧光标记之前,通过醛首先固定细胞,然后用Tx100进行透明化。在这里,我们报告了一种创新的免疫荧光标记策略,具有有意义的改变,即首先用TX100治疗细胞并以后用醛固定。我们证明这种微妙的变化可以大大提高微管免疫标记的特异性。然而,如果使用过量的TX100,则首先用TX100处理细胞也可以严重破坏微管的完整性。因此,TX100是在免疫荧光标记的“双刃剑”的微管状标记,并且需要阐述其剂量的阐述。在实验中,我们使用各种细胞系比较了不同的免疫荧光标记方案,发现在固定前用0.02%TX100处理细胞是最佳溶液。共聚焦激光扫描显微镜(CLSM),原子力显微镜(AFM)和单分子定位显微镜(SMLM)用于验证通过所呈现的异常方案进行的免疫荧光标记结果。这种微管的这种改性的免疫荧光标记方案可能是普遍的策略。

著录项

  • 来源
    《RSC Advances》 |2017年第63期|共12页
  • 作者单位

    Southeast Univ Adv Photon Ctr Nanjing 210096 Jiangsu Peoples R China;

    Southeast Univ Adv Photon Ctr Nanjing 210096 Jiangsu Peoples R China;

    Southeast Univ Adv Photon Ctr Nanjing 210096 Jiangsu Peoples R China;

    Southeast Univ Adv Photon Ctr Nanjing 210096 Jiangsu Peoples R China;

    Southeast Univ Adv Photon Ctr Nanjing 210096 Jiangsu Peoples R China;

    Southeast Univ Adv Photon Ctr Nanjing 210096 Jiangsu Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 化学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号